Lars Hellerung Christiansen

Lars Hellerung Christiansen is a Danish biotech entrepreneur and investor with more than 30 years of experience in founding, financing, and developing life-science companies. He co-founded Neumirna Therapeutics in 2020 alongside Dr. Henrik Klitgaard and Prof. Sakari Kauppinen, a Copenhagen-based biotech company focused on developing RNA-based therapies to treat neurological diseases, particularly epilepsy and Parkinson's disease using microRNA-targeted therapeutics.

Before his work in miRNA therapeutics, Christiansen was Senior Director of miRNA Research & Drug Discovery at Santaris Pharma (acquired by Roche in 2014), where he supervised the discovery of Miravirsen, the world's first miRNA-targeted drug. As a key member of the clinical development team, he played a pivotal role in advancing Miravirsen to Phase 2 clinical trials, demonstrating on-target efficacy against HCV infection.

Career History

• Co-founded Acadia Pharmaceuticals in 1995, which later became a NASDAQ-listed company with a market capitalization of $6 billion
• Co-founded Zealand Pharma in 1997, a peptide-based medicine company that achieved IPO on NASDAQ
• Co-founded Symphogen, Epizyme, Biograil and Prosidion, with Prosidion merging with OSI Pharmaceutical, which was acquired by Astellas Pharma for USD 4 billion
• Senior Director of miRNA Research & Drug Discovery at Santaris Pharma (acquired by Roche in 2014)
• Advisor and investor at Biograil, a Danish drug delivery startup

In 2017, Lars was nominated for the E&Y life sciences entrepreneur of the year award. His track record includes involvement in three NASDAQ-listed companies and multiple privately held ventures developing innovative therapeutics and drug-delivery technologies. What Lars Hellerung Christiansen could bring to Neumirna Therapeutics: His extensive track record in scaling biotech ventures from discovery through public markets, combined with his direct experience advancing the first miRNA-targeted drug through clinical development at Santaris Pharma, positions him uniquely to guide Neumirna's RNA-based neurological therapies from early stage toward clinical validation and commercialization.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.